• 6348 Citations
  • 40 h-Index
1993 …2020

Research output per year

If you made any changes in Pure these will be visible here soon.

Fingerprint Dive into the research topics where Siqing Fu is active. These topic labels come from the works of this person. Together they form a unique fingerprint.

  • 14 Similar Profiles

Network Recent external collaboration on country level. Dive into details by clicking on the dots.

Research Output

Berzosertib plus gemcitabine versus gemcitabine alone in platinum-resistant high-grade serous ovarian cancer: a multicentre, open-label, randomised, phase 2 trial

Konstantinopoulos, P. A., Cheng, S. C., Wahner Hendrickson, A. E., Penson, R. T., Schumer, S. T., Doyle, L. A., Lee, E. K., Kohn, E. C., Duska, L. R., Crispens, M. A., Olawaiye, A. B., Winer, I. S., Barroilhet, L. M., Fu, S., McHale, M. T., Schilder, R. J., Färkkilä, A., Chowdhury, D., Curtis, J., Quinn, R. S. & 4 others, Bowes, B., D'Andrea, A. D., Shapiro, G. I. & Matulonis, U. A., Jul 2020, In : The lancet oncology. 21, 7, p. 957-968 12 p.

Research output: Contribution to journalArticle

  • 2 Scopus citations

    Cell-free circulating tumor DNA variant allele frequency associates with survival in metastatic cancer

    Pairawan, S., Hess, K. R., Janku, F., Sanchez, N. S., Shaw, K. R. M., Eng, C., Damodaran, S., Javle, M., Kaseb, A., Hong, D. S., Subbiah, V., Fu, S., Fogelman, D., Raymond, V. M., Lanman, R. B. & Meric-Bernstam, F., Apr 15 2020, In : Clinical Cancer Research. 26, 8, p. 1924-1931 8 p.

    Research output: Contribution to journalArticle

  • 1 Scopus citations
    Open Access
  • First-in-man phase I trial of the selective MET inhibitor tepotinib in patients with advanced solid tumors

    Falchook, G. S., Kurzrock, R., Amin, H. M., Xiong, W., Fu, S., Piha-Paul, S. A., Janku, F., Eskandari, G., Catenacci, D. V., Klevesath, M., Bruns, R., Stammberger, U., Johne, A., Bladt, F., Friese-Hamim, M., Girard, P., Bawab, S. E. & Hong, D. S., Mar 15 2020, In : Clinical Cancer Research. 26, 6, p. 1237-1246 10 p.

    Research output: Contribution to journalArticle

    Open Access
  • 6 Scopus citations

    Phase 2 study of pembrolizumab in patients with advanced rare cancers

    Naing, A., Meric-Bernstam, F., Stephen, B., Karp, D. D., Hajjar, J., Rodon Ahnert, J., Piha-Paul, S. A., Colen, R. R., Jimenez, C., Raghav, K. P., Ferrarotto, R., Tu, S. M., Campbell, M., Wang, L., Sabir, S. H., Tapia, C., Bernatchez, C., Frumovitz, M., Tannir, N., Ravi, V. & 20 others, Khan, S., Painter, J. M., Abonofal, A., Gong, J., Alshawa, A., McQuinn, L. M., Xu, M., Ahmed, S., Subbiah, V., Hong, D. S., Pant, S., Yap, T. A., Tsimberidou, A. M., Dumbrava, E. E. I., Janku, F., Fu, S., Simon, R. M., Hess, K. R., Varadhachary, G. R. & Amir Habra, M., Mar 1 2020, In : Journal for immunotherapy of cancer. 8, 1

    Research output: Contribution to journalArticle

    Open Access
  • 4 Scopus citations